Hepatic encephalopathy as a complication of liver disease

Stephan vom Dahl, Gerald Kircheis and Dieter Haussinger

INTRODUCTION

Hepatic encephalopathy (HE) is a frequent complication of chronic liver disease. It is defined as a characteristic functional and reversible alteration of the mental state, due to impaired liver function and/or increased portosystemic shunting.

In the brain of HE patients, neurons appear morphologically normal, but astrocytes show signs of Alzheimer type II degeneration, i.e. nuclear enlargement, peripheral margination of chromatin and prominent nucleoli. Ammonia is generally considered to play a central role in the pathophysiology of HE[1]. In HE, selective alterations of blood-brain barrier permeability, changes in cerebral energy metabolism, an increased GABA-ergic tone, changes in neurotransmitter systems and alterations of gene expression, e.g. of monoamine oxidase, peripheral-type benzodiazepine receptor (PTBR) and neuronal NO synthase are found (reviewed in[1-10]). The reversibility of HE symptoms and the reason for its precipitation by a variety of different factors has not been sufficiently explained yet (Table 1). Central insights into the etiology of HE have arisen from recent in vitro work with astrocytes. Astrocytes are important constituents of the blood-brain barrier, and uptake of substances from the blood into the brain is achieved by transastrocytic transport. Astrocytes communicate directly with neurons[11], regulate neurotransmitter processing and ionic milieu and provide substrates for neurons[12,13]. In brain, astrocytes are the only cells containing glutamine synthetase[14] and represent the major site of cerebral ammonia detoxification. Upon exposure to ammonia, cultured astrocytes develop Alzheimer type II changes. These findings prompted the idea that HE is a disorder of glial cells with a consecutive neuronal dysfunction[7,15,16].

Although the symptoms of HE in acute or chronic liver failure are different, there are good reasons to assume that the pathophysiology of both conditions is similar, but may involve different kinetics. In acute liver failure, astrocytes swell and brain edema develops[17]. HE in chronic liver disease is not accompanied by clinical signs of cerebral edema, but evidence for increased cell hydration has been given, as described later. A disturbance of astrocyte hydration is apparently a major pathophysiologic event in both forms.

MRS FINDINGS IN HE

MR-spectroscopy (H-MRS) studies in human brain initiated the idea that a disturbance of astrocyte cell volume homeostasis could be decisive for development of chronic HE[18-20]. 1H-MRS can be used to study metabolic abnormalities in the human brain in vivo and allows a myo-inositol signal to be picked up, which represents an osmosensitive myo-inositol pool[19] of predominantly glial origin[21]. Myo-inositol is an organic osmolyte in astrocytes[22-24]. Such organic osmolytes play a decisive role in cell volume regulation: upon shrinkage, they accumulate inside the cells, in response to cell swelling they can be released from the cells via osmoregulated membrane channels[25,26]. Consistently, in vivo 1H-MRS studies on the brain from cirrhotic patients with HE show a depletion of myo-inositol which is accompanied by an increase in the glutamine/glutamate signal[18,19,27,30], as shown in Figure 1. On the other hand, in cirrhotic patients, the implantation of transjugular intrahepatic-stent-shunt (TIPS) may lead to an aggravation of 1H-MRS changes (Figure 2)[18] and a normalization of MRS findings after transplantation has been described[30]. In vitro studies from the rat have shown similar alterations after portocaval shunting[28]. There is a good correlation between the extent of these 1H-MRS changes and the clinical severity of HE[18,19,29,30]. An increased glutamine/glutamate signal, together with adecrease of myo-inositol signal, is observed in patients after TIPS implantation[18], as depicted in Figure 2. A high sensitivity and specificity of the myo-inositol signal for the diagnosis of HE cirrhotics has been reported[29,30], but these changes have also been reported in asymptomatic stages of hepatic encephalopathy[18,19,29,30].
IMPAIRED CELL VOLUME HOMEOSTASIS IN HE AND FUNCTIONAL CONSEQUENCES FOR ASTROCYTES

The MRS findings in HE make an impaired cell volume homeostasis in brain likely and suggest that cellular non-cytotoxic edema\(^\text{[31]}\) is present in hepatic encephalopathy. This edema is the result of an osmotically active intracellular accumulation of glutamine in response to hyperammonemia and a consecutive depletion of releasable myo-inositol and probably other osmolytes. Astrocytes swell in presence of ammonia\(^\text{[7,32]}\).

Ammonia induces brain edema and intracranial hypertension in the portocaval shunted rat \textit{in vivo} in a largely methionine sulfoximine-sensitive way\(^\text{[33]}\). PET studies with \(^{15}\text{N}\)-ammonia on human brain from encephalopathic patients showed an increased cerebral metabolic rate for ammonia, suggestive of enhanced cerebral uptake of ammonia in HE and a stimulation of glutamine synthesis\(^\text{[34]}\).

Astrocyte swelling also occurs \textit{in vitro} under the influence of hyponatremia\(^\text{[35,36]}\), some neurotransmitters\(^\text{[35,37]}\), TNF-\(\alpha\)\(^\text{[38]}\) and benzodiazepines\(^\text{[7,37]}\). Apart from myo-inositol, recent data suggest that other organic osmolytes, such as taurine\(^\text{[21,22]}\) and \(\alpha\)-glycerophosphorylcholine\(^\text{[22,39]}\), are depleted in order to counteract astrocyte swelling in HE. Small increases in astrocyte water content, as may occur in HE, could already have important functional consequences despite the absence of clinically overt increased intracranial pressure. Cell hydration is an independent signal which regulates cell function and gene expression, reviewed in\(^\text{[40-43]}\) and a variety of different osmosignalling pathways linking cell hydration and cell function have been identified\(^\text{[44]}\). Extensive work from this laboratory has described the impact of cell hydration on cell function, cytoskeleton and gene expression\(^\text{[45]}\), mainly in liver. In brain, cell hydration is also considered a key trigger of cell function. Swelling of astrocytes in culture activates virophosphatidylinositol-3-kinase extracellular regulated protein kinases (Erks)\(^\text{[36]}\), i.e. members of the MAP kinase family with multiple functions, elevates intracellular calcium concentrations\(^\text{[46]}\) and upregulates the peripheral type benzodiazepine receptor (PBR, reviewed in\(^\text{[47]}\)) at the level of agonist binding\(^\text{[48]}\) and mRNA (D. Häussinger and R. Fischer, unpublished results). Further, astrocyte swelling increases the pH in endocytotic vesicles\(^\text{[49]}\) in an Erk-dependent osmosignalling pathway (R. Fischer and D. Häussinger). Several key findings in HE can thus partially be explained by an increase of astrocyte hydration. The endosomal alkalinization following astrocyte swelling could affect receptor densities and neurotransmitter processing and swelling-induced changes of the activity of plasma membrane transporters may underlie the selective changes in “blood-brain barrier” permeability of HE. Cell swelling stimulates glycogen synthesis and inhibits

**Figure 1** Parietal \(^1\text{H}\)-MNR spectra from (A) a healthy person, patients with posthepatitic cirrhosis and latent (subclinical) HE (B) and manifest grade I-II HE (C). An increase in the glutamine/glutamate signal (Glx) and a decrease of the inositol signal (Ino) is observed. Further abbreviations: Cho, choline; Cr, creatine; N-acetylaspartate (NAA)\(^\text{[18]}\).

**Figure 2** Parietal \(^1\text{H}\)-MNR spectra from a 47-year-old patient with alcoholic cirrhosis 3 days before and 7 days after implantation of TIPS, showing an increased Glx signal and a decreased Ino signal. For abbreviations see Figure 1\(^\text{[18]}\).
glycogenolysis$^{45,50}$ and the increased deposition of glycogen in astrocytes in animal models of chronic HE$^7$ may reside on cell swelling. Astrocyte swelling leads to an increased expression of PBR and augments the synthesis of neurosteroids, which are potent modulators of neuronal GABA_A activity$^7$. Thus the interaction between astrocyte swelling, PBR expression and increased neurosteroid synthesis may explain the increased GABA_A-ergic tone in HE$^{9,51}$.

### Table 1 Precipitating factors of HE

- Gastrointestinal or tissue bleeding
- Protein overload
- Sepsis
- Infection
- Catabolism
- Azotemia
- Acidosis
- Sedatives
- Diuretics
- Portocaval shunting (TIPS or surgical)
- Constipation

### ASTROCYTE SWELLING AS AN INTEGRATIVE SIGNAL OF HE

An increase in astrocyte hydration, i.e. a low-grade cerebral edema, is a major pathogenetic event in the development of HE and induces a profound alteration of astrocyte function$^{20}$. Altered astrocyte function may eventually lead to a disturbance of glioneuronal communication and present as the clinical syndrome of HE. Bleeding, infection, sedatives or electrolyte imbalance may precipitate HE in the cirrhotic patient (Table 1). Apart from ammonia, an increase of astrocyte hydration is also induced by hyponatremia, benzodiazepines and cytokines. Multiple factors could thus obviously result in a common pathogenetic endpoint, i.e. glial swelling with its functional consequences. The osmolyte systems for counteraction of cell swelling are intact in non-cirrhotics and the precipitating conditions are well tolerated. In cirrhosis, however, organic osmolyte depletion is observed in order to compensate for glial glutamine accumulation and further challenges of cell volume can hardly be counteracted. The ^1^H-MRS findings in nonecephalopathic cirrhotics could represent an early stage of a largely compensated disturbance of astrocyte volume homeostasis, where only few consequences yet for astrocyte hydration and function are observed. In response to HE-precipitating factors, a dysequilibrium of astrocyte volume results and hydration-dependent alterations of glial function will become clinically apparent. This unstable situation may explain the rapid kinetics of HE episodes and why severe brain edema with fatal outcome can occasionally develop in endstage cirrhotics$^{52}$.

### DIAGNOSIS AND GRADING OF HE

Usually, HE is due to extensive porto-venous collateral shunting together with a decrease in hepatic function, resulting in increased cerebral ammonia load and diminished ammonia detoxification. Fulminant hepatic failure (FHF) means acute liver failure accompanied by hepatic encephalopathy. Sometimes, HE may be the result of metastatic liver disease$^{53}$, portal vein thrombosis$^{54}$, congestive heart failure$^{55}$ or constrictive pericarditis$^{56}$. Even in the absence of overt liver disease, portosystemic shunting can induce HE$^{57}$, reviewed in$^{58}$. Pre-TIPS encephalopathy is an important predictor of death during follow-up after placement of TIPS$^{59}$.

The symptoms of encephalopathy in all of these circumstances are characteristic, but unspecific. They range from subtle neuropsychologic derangements to coma. The diagnosis is made by the recognition of an appropriate hepatic disorder and the presence of encephalopathy in the absence of any other likely non-hepatic causes.

Foetor hepaticus and an increased blood ammonia concentration may contribute to the diagnosis.

For study purposes, an exact quantification of HE is required and defined by the West Haven Criteria$^{60,61}$. The PSE index comprises the mental state, asterixis, number connection test results, electroencephalography and arterial blood ammonia concentrations. Subclinical hepatic encephalopathy (SHE) can only be diagnosed by subtle neuropsychological testing$^{62}$. Preliminary results show that hepatic retinopathy, as detected by neurophysiological testing, very sensitively reflects the degree of HE (G. Kircheis and D. H-ussinger, unpublished observation) and responds to HE therapy. At the bedside, HE grade I is characterized by desorientation, whereas grade II HE shows spontaneous or inducible asterixis. In HE grade III, the patient is somnolent, grossly desoriented and precomatose, whereas grade IV represents coma.

### THERAPY OF HE

Treatment of HE focusses on the pathogenetic events present in the individual patient. The most important therapeutic approach is to identify the precipitating factors (Table 1) and to treat them vigorously. The required measures for precipitating factors are: therapy of GI bleeding together with bowel cleaning by lactulose, antibiotic treatment of concurrent infection, protein restriction, parenteral nutrition by an i.v. line and discontinuation of any diuretic therapy or sedatives. In patients with deterioration of HE after TIPS implantation, a
transcarbamylase activity and a positive effect of blood ammonia and increases liver ornithine experimental cirrhosis, zinc supplementation reduces only modest success in some patients. In a recent randomized crossover trial, plasma ammonia and nitrogen balance were significantly better on vegetable protein diet as compared to an isonitrogenous animal protein diet. Neomycin is equally effective as lactulose, but a placebo-controlled trial on neomycin showed little effectivity. In studies on oral branched-chain amino acids (BCAA) showed clinical improvement of latent or low-grade HE, even for subclinical encephalopathy, but the beneficial effect of lactulose has not been precisely shown versus placebo, reviewed in. Benzodiazepine receptor antagonists have been reported to be of value in HE but, to date with conflicting data exist on the efficacy of most antagonists. A positive effect of ammonium has not been precisely shown in the treatment of HE and liver disease. Reference 13 Kimelberg H, Ransom BR, ed. Neuroglia. New York: Academic Press, 1993.

References
1 Butterworth RF, Giguerre JF, Michaud J, Lavoie J, Layrargue GP. Ammonia: key factor in the pathogenesis of hepatic encephalopathy. Neurochem Pathol, 1987;6:1-12.
2 Basile AS, Jones EA. Ammonia and GABA-ergic neurotransmission: interrelated factors in the pathogenesis of hepatic encephalopathy. Hepatology, 97;25:1303-1305.
3 Ferenci P, Puspok A, Steinidt P. Current concepts in the pathogenesis of hepatic encephalopathy. Eur J Clin Invest, 1992;22:573-581.
4 Lockwood AH. Hepatic encephalopathy. Boston: Butterworth-Heinemann, 1992.
5 Jalan R, Seery JP, Taylor-Robinson SD. Pathogenesis and treatment of chronic hepatic encephalopathy. Aliment Pharmacol Ther, 1996;10:681-694.
6 Noreen BD, Neary JT, Dember RS. Hepatic encephalopathy: a disorder of the glial-neuronal communication. In: Lang F, Häussinger D, eds. Interactions by proton magnetic resonance spectroscopy. Physiol Rev, 1995;75:853-871.
7 Paredes A, Manusman M, Kwon HM, Strange K. Osmoregulation of Na⁺/water cotransporter activity in brain cells. Am J Physiol, 1992;263:C1282-C1286.
8 Burg MB. Molecular basis of osmotic regulation. Am J Physiol, 1995;268:F983-996.
9 Lang F, Busch GL, Ritter M, Volki H, Waldegger S, Gablinis E, Hüssinger D. Functional significance of cell volume regulatory mechanisms. Physiol Rev, 1998;78:247-306.
10 Kreis F, Rarrow NA, Ross BD. Diagnosis of hepatic encephalopathy by proton magnetic resonance spectroscopy. Lancet, 1990; 336:635-636.
11 Moats RA, Lien YH, Filippi D, Ross BD. Decrease in cerebral edema in rats and humans. Biochem J, 1993;295:15-18.
12 Ross BD, Jacobson S, Villami F, Koral J, Kreis R, Ernst T. Subclinical hepatic encephalopathy: proton MR spectroscopic. Am J Physiol, 1995;268:F983-996.
13 Ross BD, Danielsen E, Blum S. Proton magnetic resonance spectroscopy: the new gold standard for diagnosis of clinical and subclinical hepatic encephalopathy. Dig Dis, 1998;14(Suppl 1):30-39.
14 Kimelberg HK. Current concepts of brain edema. J Neurosurg, 1983:1051-1059.
15 Noreen BD, Baker L, Noreen LOB, Blicharska J, Bruce Gregories JH, Neary JT. Ammonia induced brain swelling in primary culture. Neurochem Res, 1991;16:833-836.
16 Blei AT, Olafsson S, Thirrien G, Butterworth RF. Ammonia induced brain edema and intracranial hypertension in rats after portacaval anastomosis. Hepatology, 1994;19:1437-1444.
17 Lockwood AH, Yap EWH, Wong HE. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metabol, 1991;11:337-341.
18 Kimelberg HK, O'Connor ER, Kettenmann H. Effects of cell volume regulatory abnormalities. J Neurosci, 1996;14;3073-3081.
19 Schliess F, Sinning R, Fischer, Schmalenbach C, Hüssinger D. Calcium dependent activation of Erk 1 and Erk 2 after hypo osmotic astrocyte swelling. J Neurosci, 1996;16:245-253.
20 Schliess F, Sinning R, Fischer, Schmalenbach C, Hüssinger D. Calcium dependent activation of Erk 1 and Erk 2 after hypo osmotic astrocyte swelling. J Neurosci, 1996;16:245-253.
21 Schliess F, Sinning R, Fischer, Schmalenbach C, Hüssinger D. Calcium dependent activation of Erk 1 and Erk 2 after hypo osmotic astrocyte swelling. J Neurosci, 1996;16:245-253.
22 Schliess F, Sinning R, Fischer, Schmalenbach C, Hüssinger D. Calcium dependent activation of Erk 1 and Erk 2 after hypo osmotic astrocyte swelling. J Neurosci, 1996;16:245-253.
23 Schliess F, Sinning R, Fischer, Schmalenbach C, Hüssinger D. Calcium dependent activation of Erk 1 and Erk 2 after hypo osmotic astrocyte swelling. J Neurosci, 1996;16:245-253.
24 Schliess F, Sinning R, Fischer, Schmalenbach C, Hüssinger D. Calcium dependent activation of Erk 1 and Erk 2 after hypo osmotic astrocyte swelling. J Neurosci, 1996;16:245-253.
glucose fluxes during cell volume regulation in perfused rat liver. Pflugers Arch., 1989;413:209-213

Hussinger D. Regulation and functional significance of liver cell volume. Prog Liver Dis., 1994;14:29-53

Hussinger D, Schliess F, Warskulat U, vom Dahl S. Liver cell hydration. Cell Biol Toxicol., 1997;13:275-287

Hussinger D, Wettstein M, Warskulat U, vom Dahl S, Noe B, Schliess F. Cell volume signalling, osmolytes and liver function. Digestion, 1997;58(Suppl 1):21-23

Hussinger D, Schliess F. Osmotic induction of signalling cascades: role in regulation of cell function. Biochem Biophys Res Comm., 1999;255:551-555

Hussinger D. The role of cellular hydration in the regulation of cell function. Biochem J., 1996;313:697-710

Fischer R, Schliess F, Haussinger D. Characterization of the hypoosmotically induced Ca²⁺ response in primary astrocytes. Glia, 1997;20:51-58

Butterworth RF. The astrocytic (&quot;quasi; peripheral type&quot;) benzodiazepine receptor: role in the pathogenesis of portal systemic encephalopathy. Neurochem Int., 2000;36:411-416

Itzhak Y, Bender AS, Noreen MG. Effect of hypoosmotic stress on peripheral benzodiazepine receptors in cultured astrocytes. Brain Res., 1994;644:221-225

Busch GL, Wiesinger H, Gulbins E, Wagner HJ, Hamprecht B, Lang F. Effect of astroglial swelling on pH of acidic intracellular compartments. Biochim Biophys Acta, 1996;1285:212-218

Baquet A, Hue L, Meijer AJ, van Woerkom GM, Plomp PJAM. Brain swelling of rat hepatocytes stimulates glycogen synthesis. J Biol Chem., 1990;265:955-959

Jones EA, Ferenci P. Hepatic encephalopathy: GABAergic neu transmission and the benzodiazepines. In: Conn HO, Bircher JO, eds. Hepatic encephalopathy: syndromes and therapies. Lansing, Michigan: Medi-Ed Press, 1995:75-100

Donovan JP, Schafer DF, Shaw BW, Sorell MF. Cerebral oedema and increased intracranial pressure in chronic liver disease. Lancet, 1998;351:719-721

Sawabe M, Kato Y, Ohashi I, Kitagawa T. Diffuse intrasinusoidal metastases of gastric carcinoma to the liver leading to fulminating hepatic failure. J Gastrointestin Liver Dis., 1994;3:27-31

Arora A, Seth S, Acharya SK, Sharma MP. Hepatic coma as a presentation of constricitive pericarditis. Am J Gastroen., 1993;88:430-432

Hasall E, Benson L, Hart M, Krieger DE. Hepatic encephalopathy after portocaval shunt in a non-cirrhotic child. J Pediatr., 1984;105:439-444

Watanabe A. Portal-systemic encephalopathy in non-cirrhotic patients: classification of clinical types, diagnosis and treatment. J Gastroenterol Hepatol., 2000;15:909-979

Chalamya N, Clark WS, Martin LG, Kamean J, Khan MA, Patel NH, Boyer TD. Determinants of mortality in patients with advanced cirrhosis after transjugular intrahepatic portosystemic shunting. Gastroenterology, 2000;118:138-144

Conn HO. The hepatic encephalopathies. In: Conn HO, ed. Hepatic encephalopathy: syndromes and therapies. Bloomington, Illinois: Medi Ed Press, 1994:1-12

Conn HO. Quantifying the severity of hepatic encephalopathy. In: Conn HO, ed. Hepatic encephalopathy: syndromes and therapies. Bloomington, Illinois: Medi Ed Press, 1994:13-26

Conn HO. Subclinical hepatic encephalopathy. In: Conn HO, ed. Hepatic encephalopathy: syndromes and therapies. Bloomington, Illinois: Medi Ed Press, 1994:27-42

Rossle M, Haag K, Ochs A, Sellinger M, Nolde G, Perarnau JM, Berger E, Blum U, Gabelmann A, Hauenstein K. The transjugular intrahepatic portosystemic shunt procedure for variceal bleeding. N Engl J Med., 1994;330:165-171

Roussie M, Piotraschke J. Transjugular intrahepatic portosystemic shunt and hepatic encephalopathy. Dig Dis., 1996;14:12-19

Dhiman RK, Sawhney MS, Chawla YK, Das G, Ram S, Dilawari JB. Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy. Dig Dis Sci., 2000;45:1549-1552

Orlandi F, Brunelli E, Benedetti A, Macarri G. Clinical trials of nonabsorbable disaccharide therapy in hepatic encephalopathy. In: Conn HO, Bircher J, eds. Hepatic encephalopathy: syndromes and therapies. Bloomington, Illinois: Medi Ed Press, 1994:243-264

Bianchi GP, Marchesini G, Fabbri A, Rondelli A, Bugianesi E, Zoli M, Pissis E. Vegetable versus animal protein diet in cirrhotic patients with chronic hepatic encephalopathy: a randomised cross over comparison. J Intern Med., 1993;233:385-392

Strauss E, Tramote R, Silva EPS, Carl WR, Honain NZ, Maffei RA, de Sa MFG. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology, 1992;39:542-545

Kircheis G, Nilius R, Held C, Berndt H, Buchner M, Grelmeyer E, Hendricks R, Krüger B, Klünski B, Meister H, Otto HJ, Rink C, Risch W, Stauch S. Therapeutic efficacy of L ornithine L aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo controlled double blind trial. Hepatology, 1997;25:1351-1360

Rees CJ, Oppong K, Al Mardini H, Hudson M, Record CO. Effect of L ornithine L aspartate on patients with and without TIPS undergoing glucose challenge: a double blind, placebo controlled trial. Gut, 2000;47:571-574

Plauth M, Egberts EH, Hamster W, Trk M, Brand O, Fürst P, Dille W. Long term treatment of latent portosystemic encephalopathy with branched chain amino acids: a double blind placebo controlled trial. J Hepatol., 1993;17:308-314

Pomier-Layrargues G, Giguerre JF, Lavoite J, Perney P, Gagnon S, D’Amour M, Well J, Butteau R, Flumazenil in cirrhotic patients with hepatic coma: a randomized double-blind placebo controlled trial. Hepatology, 1994;19:32-37

Ferenci P, Grimm G, Meryn S, Gangl A. Successful long-term treatment of portal systemic encephalopathy by the benzodiazepine antagonist flumazenil. Gastroenterology, 1989;96:240-243

Riggi O, Merli M, Capocaccia L. Zinc supplementation reduces blood ammonia and increase liver ornithine transcarbamylase activity in experimental cirrhosis. Hepatology, 1992;16:785-789

Reding P, Duchateau J, Bataille C. Oral zinc supplementation improves hepatic encephalopathy. Lancet, 1984;2:493-494

Edited by Ma JY